Combining Human Urinary Kallidinogenase with Endovascular Therapy for Acute Ischemic Stroke
Official title: Efficacy and Safety of Human Urinary Kallidinogenase Combined With Endovascular Therapy in Acute Ischemic Stroke With Large Vessel Occlusion: A Prospective, Randomized, Double-blind, Placebo-controlled, Multi-center Study
Run by Huashan Hospital · NCT06211712 · Data updated 2026-11-12
This study is testing if adding a new treatment called Human Urinary Kallidinogenase to standard endovascular therapy can help people who have had a severe stroke caused by a blocked blood vessel.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Huashan Hospital Academic / other |
| Locations | 1 site (Shanghai) |
| Status | Recruiting |
| Started | April 17, 2024 |
| Main results expected | June 2025 |
| Study ends | December 2025 |
| Registry record updated | December 4, 2024 |
| Trial ID | NCT06211712 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older who have experienced an acute anterior circulation ischemic stroke and are receiving endovascular treatment within 24 hours.
✕Probably not a fit
Patients with severe organ dysfunction, coagulation disorders, or contraindications to the treatment will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the safety and efficacy of Human Urinary Kallidinogenase when used alongside endovascular therapy in patients suffering from acute ischemic stroke due to large vessel occlusion. It is a prospective, randomized, double-blind, placebo-controlled, multi-center trial involving approximately 120 participants. Patients will be assigned to receive either the experimental treatment or a placebo for a duration of 10 days, with primary efficacy assessed at 90 days post-treatment. Safety evaluations will also be conducted over the same period.
Why it matters
Potential benefit: If successful, this treatment could significantly improve recovery outcomes for patients with acute ischemic stroke.
How similar studies have gone: While this approach is innovative, similar studies have shown promise in the treatment of acute ischemic stroke, suggesting potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Participant with acute anterior circulation ischemic stroke receiving endovascular treatment within 24 hours (non-bridged). 2. Age ≥18 years old. 3. The mRS score was 0-1 before onset. 4. ASPECT score of infarction on emergency CT ≥7. 5. Emergency CTA indicating AIS with large vessel occlusion (internal carotid artery, M1 or M2 segment of middle cerebral artery). 6. Emergency CTP or DWI suggesting infarct core body ≥10 mL and \<100 mL, and low perfusion brain tissue volume/ infarct core volume\> 1.2. 7. Participant is willing and able to comply with the study protocol, and sign the informed consent form (patient or surrogate). Exclusion Criteria: 1. Participant with severe heart, liver and kidney dysfunction, coagulation dysfunction, intolerance to surgery, Human Urinary Kallidinogenase allergy, contrast agent allergy or other angiographic contraindications. 2. CT or MRI showed intracranial hemorrhagic diseases (such as hemorrhagic stroke, epidural hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, etc.). 3. Participant with previous cerebral hemorrhage, brain tumor, brain trauma or other brain diseases. 4. Taking ACEI antihypertensive drugs regularly and could not stop. 5. Participant with major surgery or severe trauma in the past 2 weeks. 6. Poor compliance and cannot fully follow the study protocol. 7. Pregnancy or lactation.
Where it's running
-
Huashan Hospital
Shanghai, China Recruiting
Study contacts
- Principal investigator: Qiang Dong, M.D. — Huashan Hospital
- Study coordinator: Qiang Dong, M.D.
- Email: 13701747065@163.com
- Phone: 13701747065
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Short-Term outside-in nerve stimulation for acute ischemic stroke
This trial tests whether a 5-day external trigeminal nerve stimulation given after stroke can help more patients recover better than a sham treatment.
-
Sevoflurane vs. Propofol for anesthesia in stroke patients undergoing clot-removal
This study tests whether sevoflurane or propofol used for anesthesia during endovascular treatment of an acute ischemic stroke affects the final brain damage and recovery.
-
Safety of adding NRICM301 to standard care for adults with acute ischemic stroke
This study tests whether adding NRICM301, a traditional Chinese medicine formula, to usual care is safe for adults with acute ischemic stroke.
-
Intracranial Recanalization with LT3001 in Acute Ischemic Stroke
This phase II study tests whether LT3001 given to adults with acute ischemic stroke can help reopen blocked brain arteries.
-
Mobilisation After Endovascular Stroke Treatment
This study checks whether moving around 12 hours after endovascular stroke treatment is as safe as moving around 24 hours for people with an acute ischemic stroke.
-
Endovascular therapy plus standard care vs standard care alone for distal and medium vessel strokes
In people with acute ischemic stroke due to distal or medium vessel blockages, this study tests whether adding endovascular treatment to the usual medical care helps improve outcomes compared with medical care alone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.